Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for CorMedix (CRMD) over the last 13 years, with Q3 2025 value amounting to $750.9 million.

  • CorMedix's Liabilities and Shareholders Equity rose 86777.72% to $750.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year increase of 33148.57%. This contributed to the annual value of $118.8 million for FY2024, which is N/A changed from last year.
  • As of Q3 2025, CorMedix's Liabilities and Shareholders Equity stood at $750.9 million, which was up 86777.72% from $252.6 million recorded in Q2 2025.
  • CorMedix's 5-year Liabilities and Shareholders Equity high stood at $750.9 million for Q3 2025, and its period low was $57.0 million during Q2 2023.
  • Over the past 5 years, CorMedix's median Liabilities and Shareholders Equity value was $72.2 million (recorded in 2021), while the average stood at $125.0 million.
  • Per our database at Business Quant, CorMedix's Liabilities and Shareholders Equity plummeted by 2293.57% in 2022 and then skyrocketed by 86777.72% in 2025.
  • Quarter analysis of 5 years shows CorMedix's Liabilities and Shareholders Equity stood at $68.9 million in 2021, then decreased by 10.02% to $62.0 million in 2022, then surged by 47.38% to $91.4 million in 2023, then grew by 29.99% to $118.8 million in 2024, then soared by 531.8% to $750.9 million in 2025.
  • Its Liabilities and Shareholders Equity was $750.9 million in Q3 2025, compared to $252.6 million in Q2 2025 and $149.6 million in Q1 2025.